BiotechTube
BioSyn

BioSyn

San Diego, United States· Est.
biosyncorp.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

BioSyn Corporation is a privately held biopharmaceutical company with a unique focus on hemocyanin and selenium-based therapeutics. Founded in 1980 and headquartered in Carlsbad, California, the company has established itself as the global leader in manufacturing high-purity KLH, a critical carrier protein and adjuvant used in over 100 clinical trials worldwide. Its vertically integrated operations include a dedicated GMP facility with specialized aquaria for the sustainable, non-lethal harvesting of Giant Keyhole Limpets. While generating revenue from research and clinical-grade product sales, BioSyn's pipeline includes its KLH products in various investigational uses and its Selenase® product for conditions like sepsis.

OncologyInfectious DiseaseSepsisCritical Care

Technology Platform

Vertically integrated, sustainable manufacturing platform for the non-lethal extraction and GMP production of Keyhole Limpet Hemocyanin (KLH) from the Giant Keyhole Limpet. Also includes pharmaceutical synthesis of sodium selenite.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

Growing demand for high-quality KLH driven by expansion in immunotherapy and conjugate vaccine R&D provides a stable growth trajectory.
The Selenase® program holds significant potential for market expansion in the U.S.
and other regions if clinical data in sepsis and critical care continues to be positive, addressing a major unmet medical need.

Risk Factors

The business is heavily reliant on a single, biologically sourced raw material (Giant Keyhole Limpet), creating supply chain vulnerability.
Revenue is also dependent on the clinical trial activity and success of partner pharmaceutical companies, making it susceptible to shifts in R&D focus and funding.

Competitive Landscape

BioSyn is the acknowledged world leader in GMP-grade KLH manufacturing, with a unique sustainable harvesting process that creates a significant barrier to entry. Competition exists from smaller suppliers of research-grade KLH and from developers of alternative carrier proteins (e.g., CRM197, TT) or recombinant KLH technologies, but BioSyn's clinical trial track record and quality standards provide a strong competitive advantage.

More companies in Biologics / Biosimilars →More companies in United States →